학술논문
Detection of NTRKfusions in glioblastoma: fluorescent in situhybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing
Document Type
Article
Author
Source
Pathology; February 2022, Vol. 54 Issue: 1 p55-62, 8p
Subject
Language
ISSN
00313025; 14653931
Abstract
Glioblastomas are frequent malignant brain tumours with a very poor prognosis and a need for new and efficient therapeutic strategies. With the approval of anti-TRK targeted therapies to treat patients with advanced NTRK-rearranged cancers, independent of the type of cancer, potential new treatment opportunities are available for the 0.5–5% of patients with NTRK-rearranged glioblastomas. Identification of these rare NTRK-rearranged glioblastomas requires efficient diagnostic tools and strategies which are evaluated in this study.